Want to see HK:2256 full AI Analyst Report?
Top Page
Abbisko Cayman Limited
(2256)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$9.00
▼(-30.88% Downside)
Action:Reiterated
Date:06/30/26
The score is primarily driven by improving fundamentals—scaled revenue, a shift toward profitability, and a low-leverage balance sheet—offset by uneven cash-flow history, a sharp year-over-year free-cash-flow decline in 2025, and slightly negative revenue growth. Technical and valuation inputs are limited/neutral due to missing indicators and no dividend yield data.
Positive Factors
Scaled Revenue Base
Revenue has developed from a very small historical base into a meaningful 2025 scale, demonstrating that the company has established commercial activity. This larger base can support operating leverage, broader investment capacity, and more durable execution if the business resumes growth.
Negative Factors
Negative Revenue Growth
The 2025 revenue decline shows that the company has not yet established a consistently expanding commercial trajectory. A weaker top line can restrict operating leverage, make fixed costs harder to absorb, and delay the conversion of recent profitability improvements into durable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Scaled Revenue Base
Revenue has developed from a very small historical base into a meaningful 2025 scale, demonstrating that the company has established commercial activity. This larger base can support operating leverage, broader investment capacity, and more durable execution if the business resumes growth.
Read all positive factors
Abbisko Cayman Limited (2256) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.37B
Dividend YieldN/A
Average Volume (3M)1.24M
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-83.32%
EPS Growth-383.82%
CountryHK
Employees286
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding726,205,300
10 Day Avg. Volume1,214,590
30 Day Avg. Volume1,243,118
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)3.79
Price to Sales (P/S)12.24
P/FCF Ratio98.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.80Price Target Upside82.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)HK$241.98M
Abbisko Cayman Limited Business Overview & Revenue Model
Company Description
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeuti...
Abbisko Cayman Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
73
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 97.27M | 596.28M | 503.99M | 19.06M | 0.00 | 22.68M |
| Gross Profit | 95.50M | 596.28M | 503.99M | 19.06M | 0.00 | 22.68M |
| EBITDA | -509.14M | 48.93M | -15.28M | -410.99M | -492.62M | -1.80B |
| Net Income | -466.69M | 53.82M | 28.30M | -431.58M | -498.29M | -1.81B |
Balance Sheet | ||||||
| Total Assets | 2.70B | 2.35B | 2.11B | 2.12B | 2.49B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.46B | 2.10B | 2.01B | 1.96B | 2.35B | 2.57B |
| Total Debt | 454.73M | 303.61M | 24.29M | 35.72M | 45.58M | 53.80M |
| Total Liabilities | 515.26M | 430.41M | 148.71M | 134.28M | 143.16M | 118.48M |
| Stockholders Equity | 2.18B | 1.92B | 1.96B | 1.98B | 2.35B | 2.54B |
Cash Flow | ||||||
| Free Cash Flow | -225.26M | 73.75M | -20.32M | -456.98M | -366.64M | -182.08M |
| Operating Cash Flow | -224.05M | 79.29M | -12.92M | -444.73M | -343.90M | -169.74M |
| Investing Cash Flow | 97.16M | 211.94M | -196.50M | 378.52M | -216.57M | -1.46B |
| Financing Cash Flow | 143.93M | 186.89M | -80.86M | -16.11M | -20.81M | 2.10B |
Abbisko Cayman Limited Technical Analysis
Negative
13.02
Price Trends
10.35
Negative
10.66
Negative
11.96
Negative
Market Momentum
-0.43
Positive
31.98
Neutral
13.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Negative. The current price of 13.02 is above the 20-day moving average (MA) of 9.98, above the 50-day MA of 10.35, and above the 200-day MA of 11.96, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 31.98 is Neutral, neither overbought nor oversold. The STOCH value of 13.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2256.
Abbisko Cayman Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$38.22B | 37.67 | 20.41% | ― | 32.63% | 8.87% | |
59 Neutral | HK$6.37B | -10.12 | -22.75% | ― | -83.32% | -383.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$808.53M | -2.07 | -66.16% | ― | 67.48% | 43.84% | |
46 Neutral | HK$8.55B | -43.59 | -10.27% | ― | -31.77% | -177.01% | |
46 Neutral | HK$34.66B | -78.10 | -7.32% | ― | 34.83% | 58.94% | |
44 Neutral | HK$7.98B | -71.50 | -9.49% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
HK:2256
Abbisko Cayman Limited
8.77
-9.34
-51.57%
HK:9966
Alphamab Oncology
8.77
-2.02
-18.72%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
18.22
-17.18
-48.53%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
1.94
-3.61
-65.05%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-9.63
-41.76%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
70.10
-18.60
-20.97%
Abbisko Cayman Limited Corporate Events
Abbisko Therapeutics Begins First-in-Human Trial of Novel Pan-KRAS Cancer Drug ABSK211
Aug 31, 2026
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has commenced first patient dosing in a Phase I clinical trial of ABSK211, an oral, highly potent small-molecule pan-KRAS inhibitor. The study targets patients with advanced solid tumor...
Abbisko Seeks Shareholder Approval to Rebrand as Abbisko Medicine Co., Ltd.
Aug 28, 2026
Abbisko Cayman Limited has called an extraordinary general meeting to seek shareholder approval for a change of its English name to Abbisko Medicine Co., Ltd., along with a corresponding change to its dual foreign Chinese name. The meeting will be...
Abbisko Cayman Advances Oncology Pipeline as Lead Drug Pimicotinib Launches in China
Aug 24, 2026
Abbisko Cayman Limited reported substantial operational progress for the six months ended June 30, 2026, highlighted by the commercial launch in China of its lead asset pimicotinib for tenosynovial giant cell tumor through a strategic partnership ...
Abbisko Proposes Rebrand to Abbisko Medicine Co., Ltd. Without Impact on Trading
Aug 24, 2026
Abbisko Cayman Limited plans to change its English name to Abbisko Medicine Co., Ltd., and adopt a new corresponding Chinese name, subject to shareholder approval at an extraordinary general meeting and the issuance of a new certificate of incorpo...
Abbisko Wins China IND Nod for Pan-KRAS Cancer Drug ABSK211
Aug 19, 2026
Abbisko Therapeutics has secured Investigational New Drug clearance from China’s National Medical Products Administration for ABSK211, an oral small-molecule pan-KRAS inhibitor intended for patients with advanced solid tumors harboring KRAS ...
Abbisko Sets August Board Meeting to Approve Interim Results and Weigh Dividend
Aug 3, 2026
Abbisko Cayman Limited has scheduled a board meeting for August 24, 2026 to review and approve its unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recomm...
Abbisko Wins FDA IND Clearance for Pan-KRAS Cancer Drug ABSK211
Jul 13, 2026
Abbisko Therapeutics has received clearance from the U.S. Food and Drug Administration for an Investigational New Drug application covering ABSK211, an oral, highly potent and selective pan-KRAS inhibitor for patients with advanced solid tumors ha...
Abbisko and AstraZeneca Launch Joint Trial of Novel NSCLC Combination
Jul 2, 2026
Abbisko Therapeutics has entered a strategic collaboration with AstraZeneca to conduct a multicenter Phase I/II clinical trial combining lumipodlin, a first‑in‑class oral PD‑L1 inhibitor, with AstraZeneca’s EGFR‑TKI T...
Abbisko Showcases Promising Phase II FGFR2-Targeted Combo Data in Advanced Gastric Cancer
Jun 26, 2026
Abbisko Therapeutics has reported preliminary Phase II data for its first-in-class oral FGFR2/3 inhibitor ABSK061 in combination with its oral PD-L1 inhibitor ABSK043, with or without CAPOX, in patients with FGFR2-positive advanced gastric and gas...
Abbisko Deepens Lilly Partnership in Multitarget Drug R&D Deal Worth Up to US$1.9 Billion
Jun 24, 2026
Abbisko Therapeutics has entered into a new strategic research collaboration and license agreement with Eli Lilly, deepening their existing partnership in innovative drug discovery. The agreement focuses on multiple disease targets, with Abbisko l...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.